Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the Aromatase P450 gene (CYP19)

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 6, 2002, Pages 2540-2548

  Shozu, Makio ^a   Sumitani, Hiroshi ^a   Segawa, Tomoya ^a   Yang, Hei Juan ^a   Murakami, Kouichi ^a   Kasai, Tadayuki ^a   Inoue, Masaki ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; COMPLEMENTARY DNA; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 1BETA; ISOBUTYLMETHYLXANTHINE; LUCIFERASE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; CYP19 GENE; DNA RESPONSIVE ELEMENT; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; HUMAN TISSUE; LEIOMYOMA; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TISSUE SPECIFICITY; TUMOR CELL; TUMOR GROWTH;

EID: 0036074954     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.6.8533     Document Type: Article

References (59)

1. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms
2. Deletion 7q22 in uterine leiomyoma. A cytogenetic review
3. Translocation (6;10)(p21;q22) in uterine leiomyomas
4. Subgroups of uterine leiomyomas based on cytogenetic analysis
5. HMGIC expressed in a uterine leiomyoma with a deletion of the long arm of chromosome 7 along with a 12q14-15 rearrangement but not in tumors showing del(7) as the sole cytogenetic abnormality
6. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata
7. Genetic basis of uterine leiomyoma: Involvement of high mobility group protein genes
8. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas
9. Allelotype analysis of uterine leiomyoma: Localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q
10. Uterine fibroids
11. Aromatase activity in uterine leiomyomata
12. Effect of aminoglutethimide on androstenedione aromatase activity in human uterine leiomyoma
13. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture
14. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism
15. Unconjugated steroids in leiomyomas and tumor-bearing myometrium
16. Effect of decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium
17. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate
18. Treatment of uterine fibroids: Current findings with gonadotropin-releasing hormone agonists
19. Effects of leuprolide acetate on treatment of leiomyomata: Clues to mechanisms of action
20. Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma
21. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women
22. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis
23. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis
24. Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years
25. Dating the endometrial biopsy
26. Maintenance and characterization of human myometrial smooth muscle cells in monolayer culture
27. Production and characterization of single-chain tissue-type plasminogen activator produced by an established cell line from human uterine muscle
28. Characterization of KW smooth muscle-like human myometrial cells
29. Estrogen biosynthesis in THP1 cells is regulated by promoter switching of the aromatase (CYP19) gene
30. TGF-β1 stimulates expression of the aromatase (CYP19) gene in human osteoblast-like cells and THP-1 cells
31. Interleukin-1 and interleukin-6 in breast cyst fluid: Their role in regulating aromatase activity in breast cancer cells
32. Aromatase expression of human osteoblast-like cells
33. Effect of interleukin-1β on aromatase activity and cell proliferation in human osteoblast-like cells (HOS)
34. 2 via cyclic AMP, leading to activation of promoter II of the CYP-19 (aromatase) gene
35. Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (CYP19)
36. 2 stimulates aromatase expression in endometriosis-derived stromal cells
37. The role of local estrogen biosynthesis in males and females
38. Do intracrine mechanisms regulate aromatase expression?
39. Local estrogen biosynthesis in males and females
40. Aromatase in the normal breast and breast cancer
41. Aromatase expression and its localization in human breast cancer
42. Aromatase gene expression in adipose tissue: Relationship to breast cancer
43. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
44. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts
45. Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis
46. Brain aromatization of androgens
47. Molecular analysis of aberrant expression of aromatase in breast cancer tissues
48. Use of aromatase inhibitors in breast carcinoma
49. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer
50. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis
51. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients
52. Cytochromes P450 11: Expression of the CYP19 (aromatase) gene: An unusual case of alternative promoter usage
53. Down-regulation of promoter I.3 activity of the human aromatase gene in breast tissues by zinc-finger protein, Snail (SnaH)
54. Serotonin-mediated production of interstitial collagenase by uterine smooth muscle cells requires interleukin-1α, but not interleukin-1β
55. Serotonin regulation of interleukin-1 messenger RNA in rat uterine smooth muscle cells. Relationship to the production of interstitial collagenase
56. Uterine leiomyomas with high content of mast cells
57. Mast cells in smooth muscle tumors of the uterus
58. Placental estrogen synthetase (aromatase): Evidence for phosphatase-dependent inactivation
59. Regulation of aromatase activity in bone-derived cells: Possible role of mitogen-activated protein kinase